Montelukast vs Nivolumab
Montelukast vs Nivolumab: Overview
This comparison examines the pharmacological differences between Montelukast and Nivolumab.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Montelukast — 2.7-5.5 hours; Nivolumab — 27 days.
Chemical Properties
Molecular Formula: Montelukast — C35H36ClNO3S.
Molecular Weight: Montelukast — 586.1800 g/mol.
Type: Montelukast — Small molecule; Nivolumab — Antibody.